{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:21:07Z","timestamp":1785187267880,"version":"3.55.0"},"reference-count":35,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Evaluate the safety and efficacy of longterm abatacept (ABA) treatment over 5 years in methotrexate (MTX)-refractory patients with rheumatoid arthritis (RA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Patients from the 1-year, double-blind Abatacept in Inadequate Responders to Methotrexate (AIM) study (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00048568\">NCT00048568<\/jats:ext-link>) received open-label ABA (\u223c10 mg\/kg) in the longterm extension (LTE). Safety was assessed for patients who received \u2265 1 ABA dose, and efficacy for patients randomized to ABA and treated in the LTE. Radiographs were evaluated for changes in Genant-modified Sharp scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Out of 652 patients, 539 entered the LTE (ABA, n = 378; placebo, n = 161). At Year 5, 72.4% were ongoing; discontinuation rates declined over time. Incidence rates of serious adverse events, serious infections, malignancies, and autoimmune events were 13.87, 2.84, 1.45, and 0.99 events\/100 patient-years exposure, respectively. American College of Rheumatology 20 response was 82.3% (n = 373) and 83.6% (n = 268) at years 1 and 5, respectively. Disease Activity Score 28 C-reactive protein (DAS28-CRP) &lt; 2.6 and \u2264 3.2 were achieved by 25.4% and 44.1% of patients at Year 1 (n = 370), and 33.7% and 54.7% at Year 5 (n = 267), respectively. Mean changes in DAS28-CRP and Health Assessment Questionnaire\u2013Disability Index at Year 1 [\u20132.83 (n = 365) and \u22120.68 (n = 369)] were maintained at Year 5 [\u22123.14 (n = 264) and \u22120.77 (n = 271)] for patients continuing treatment. Of them, 59.5% (n = 291) and 45.1% (n = 235) remained free from radiographic progression at years 1 and 5, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>In MTX-refractory patients with RA, longterm ABA treatment was well tolerated and provided consistent safety and sustained efficacy, with high patient retention. Radiographic progression continued to be inhibited with ongoing treatment.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.130263","type":"journal-article","created":{"date-parts":[[2014,5,2]],"date-time":"2014-05-02T03:35:07Z","timestamp":1399001707000},"page":"1077-1087","source":"Crossref","is-referenced-by-count":29,"title":["Longterm Safety, Efficacy, and Inhibition of Structural Damage Progression Over 5 Years of Treatment with Abatacept in Patients with Rheumatoid Arthritis in the Abatacept in Inadequate Responders to Methotrexate Trial"],"prefix":"10.3899","volume":"41","author":[{"given":"Joel M.","family":"Kremer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Peterfy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Abud-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Sibilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Westhovens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry K.","family":"Genant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2014,5,1]]},"reference":[{"key":"2018112909325346000_41.6.1077.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091454"},{"key":"2018112909325346000_41.6.1077.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21201"},{"key":"2018112909325346000_41.6.1077.3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-12-200606200-00003"},{"key":"2018112909325346000_41.6.1077.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080002"},{"key":"2018112909325346000_41.6.1077.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.23397"},{"key":"2018112909325346000_41.6.1077.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139345"},{"key":"2018112909325346000_41.6.1077.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200316"},{"key":"2018112909325346000_41.6.1077.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080813"},{"key":"2018112909325346000_41.6.1077.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.085084"},{"key":"2018112909325346000_41.6.1077.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"2018112909325346000_41.6.1077.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.001"},{"key":"2018112909325346000_41.6.1077.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780261107"},{"key":"2018112909325346000_41.6.1077.13","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1583::AID-ART8>3.0.CO;2-H"},{"key":"2018112909325346000_41.6.1077.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.038349"},{"key":"2018112909325346000_41.6.1077.15","doi-asserted-by":"publisher","DOI":"10.1186\/ar2001"},{"key":"2018112909325346000_41.6.1077.16","doi-asserted-by":"publisher","DOI":"10.1186\/ar2997"},{"key":"2018112909325346000_41.6.1077.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.044404"},{"key":"2018112909325346000_41.6.1077.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"2018112909325346000_41.6.1077.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.05.002"},{"key":"2018112909325346000_41.6.1077.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg263"},{"key":"2018112909325346000_41.6.1077.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.21386"},{"key":"2018112909325346000_41.6.1077.22","doi-asserted-by":"publisher","DOI":"10.1186\/ar2404"},{"key":"2018112909325346000_41.6.1077.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.089276"},{"key":"2018112909325346000_41.6.1077.24","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282f4b392"},{"key":"2018112909325346000_41.6.1077.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101009"},{"key":"2018112909325346000_41.6.1077.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201338"},{"key":"2018112909325346000_41.6.1077.27","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21812"},{"key":"2018112909325346000_41.6.1077.28","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120906"},{"issue":"Suppl 10","key":"2018112909325346000_41.6.1077.29","first-page":"S164","article-title":"Long-term safety of abatacept: integrated analysis of clinical program data of up to 7 years of treatment","volume":"62","author":"Hochberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2018112909325346000_41.6.1077.30","doi-asserted-by":"crossref","unstructured":"Singh JA Christensen R Wells GA Suarez-Almazor ME Buchbinder R Lopez-Olivo MA Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;CD007848.","DOI":"10.1002\/14651858.CD007848"},{"key":"2018112909325346000_41.6.1077.31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.2.122"},{"key":"2018112909325346000_41.6.1077.32","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L"},{"key":"2018112909325346000_41.6.1077.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.123919"},{"key":"2018112909325346000_41.6.1077.34","doi-asserted-by":"publisher","DOI":"10.1002\/anr.1780320603"},{"key":"2018112909325346000_41.6.1077.35","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143420"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.130263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:36:37Z","timestamp":1543516597000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.130263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,1]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6,1]]},"published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.3899\/jrheum.130263"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.130263","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,1]]}}}